<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Artemether and lumefantrine: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Artemether and lumefantrine: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Artemether and lumefantrine: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9066" href="/d/html/9066.html" rel="external">see "Artemether and lumefantrine: Drug information"</a> and <a class="drug drug_patient" data-topicid="10843" href="/d/html/10843.html" rel="external">see "Artemether and lumefantrine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F7695214"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Coartem</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F7765626"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antimalarial Agent</span></li></ul></div>
<div class="block dop drugH1Div" id="F7725883"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8766acfb-a2c1-4ac2-b4a3-ffdf831de51e">Malaria, treatment, uncomplicated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Malaria, treatment, uncomplicated (due to <i>P. falciparum</i>, including chloroquine resistant <i>P. falciparum</i>):</b>
<b>Note:</b> Not for treatment of severe or complicated <i>Plasmodium falciparum</i> malaria or prevention of malaria.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥2 months, Children, and Adolescents: <b>Note: </b>Additional tablet strengths may be available outside the US:</p>
<p style="text-indent:-2em;margin-left:6em;">Oral (artemether 20 mg/lumefantrine 120 mg per tablet):</p>
<p style="text-indent:-2em;margin-left:8em;">5 kg to &lt;15 kg: One tablet at hour 0 and at hour 8 on the first day and then one tablet twice daily (in the morning and evening) on days 2 and 3 (total of 6 tablets per treatment course).</p>
<p style="text-indent:-2em;margin-left:8em;">15 kg to &lt;25 kg: Two tablets at hour 0 and at hour 8 on the first day and then two tablets twice daily (in the morning and evening) on days 2 and 3 (total of 12 tablets per treatment course).</p>
<p style="text-indent:-2em;margin-left:8em;">25 kg to &lt;35 kg: Three tablets at hour 0 and at hour 8 on the first day and then three tablets twice daily (in the morning and evening) on day 2 and 3 (total of 18 tablets per treatment course).</p>
<p style="text-indent:-2em;margin-left:8em;">≥35 kg: Four tablets at hour 0 and at hour 8 on the first day and then four tablets twice daily (in the morning and evening) on days 2 and 3 (total of 24 tablets per treatment course).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51065154"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Dosage adjustments are not recommended in mild or moderate impairment. Use caution in severe impairment (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F51065155"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Dosage adjustments are not recommended in mild or moderate impairment. Use caution in severe impairment (has not been studied).</p></div>
<div class="block doa drugH1Div" id="F7725928"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9066" href="/d/html/9066.html" rel="external">see "Artemether and lumefantrine: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="907db476-c453-431b-8e3f-050c1461baaf">Malaria, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Malaria, treatment:</b>
<b>Oral:</b> Artemether 80 mg/lumefantrine 480 mg twice daily for 3 days; ideally, the first 2 doses should be administered 8 hours apart (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2','lexi-content-ref-WHO.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2','lexi-content-ref-WHO.1','lexi-content-ref-manu.1'])">Ref</a></span>). For <i>P. vivax</i> or <i>P. ovale</i>, use in combination with primaquine. If used for severe malaria (after completion of IV therapy), use full 3-day schedule in addition to IV therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2','lexi-content-ref-WHO.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2','lexi-content-ref-WHO.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990949"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Dosage adjustments are not recommended in mild or moderate impairment. Use caution in severe impairment (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50988286"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Dosage adjustments are not recommended in mild or moderate impairment. Use caution in severe impairment (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F7725705"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:0em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Palpitation (adults: 18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (adults 56%; children 13%), dizziness (adults 39%; children 4%), fever (25% to 29%), chills (adults 23%; children 5%), sleep disorder (adults: 22%), fatigue (adults 17%; children 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia (adults 40%; children 13%), nausea (adults 26%; children 5%), vomiting (17% to 18%), abdominal pain (8% to 17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Plasmodium falciparum (exacerbation: children: 17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Weakness (adults 38%; children 5%), arthralgia (adults 34%; children 3%), myalgia (adults 32%; children 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (adults 6%; children 23%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (25% to 29%)</p>
<p style="text-indent:-2em;margin-left:2em;">3% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Insomnia (adults: 5%), malaise (adults: 3%), vertigo (adults: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (adults: 4%), skin rash (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (7% to 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (4% to 9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatomegaly (6% to 9%), increased serum AST (≤4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Malaria (≤3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Rhinitis (4%), nasopharyngitis (≤3%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;3%, postmarketing, and/or case reports: Abnormal gait, abnormal lymphocytes, abscess, agitation, anaphylaxis, angioedema, asthma, ataxia, back pain, bronchitis, bullous dermatitis, change in platelet count (increased), clonus, conjunctivitis, constipation, decreased hematocrit, decreased platelet count, decreased white blood cell count, dermatitis (hands and feet), dyspepsia, dysphagia, emotional lability, eosinophilia, fine motor control disorder, gastroenteritis, helminthiasis, hematuria, hemolytic anemia (delayed), hookworm infection, hyper-reflexia, hypoesthesia, hypokalemia, impetigo, increased serum ALT, influenza, leukocytosis, leukopenia, lower respiratory tract infection, nystagmus, oral herpes, otic infection, peptic ulcer, pharyngolaryngeal pain, pneumonia, proteinuria, respiratory tract infection, subcutaneous abscess, tinnitus, tremor, upper respiratory tract infection, urinary tract infection, urticaria</p></div>
<div class="block coi drugH1Div" id="F7725582"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to artemether, lumefantrine, or any component of the formulation; concurrent use with strong CYP3A4 inducers (eg, rifampin, carbamazepine, phenytoin, St John’s wort)</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F7725583"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• QT prolongation: Use associated with prolonging the QT interval; avoid use in patients at risk for QT prolongation, including patients with a history of long QT syndrome, family history of congenital QT prolongation or sudden death, symptomatic arrhythmias, clinically relevant bradycardia, severe heart disease, known hypokalemia, hypomagnesemia or concurrent administration of antiarrhythmics (eg, Class Ia or III), drugs metabolized by CYP2D6 known to have cardiac effects (eg, flecainide, tricyclic antidepressants), or other drugs known to prolong the QT interval (eg, antipsychotics, antidepressants, macrolides, fluoroquinolones, triazole antifungals, or cisapride).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use caution in patients with severe hepatic impairment; has not been adequately studied.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use caution in patients with severe renal impairment; has not been adequately studied.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Drugs that prolong the QT interval: Avoid use in patients receiving other agents that prolong the QT interval; consider alternative therapy. ECG monitoring is advised if concomitant use of agents that prolong the QT interval is medically required. In addition, do not use halofantrine (not available in the US) and artemether/lumefantrine within one month of one another due to the potential additive effects on the QT interval. After discontinuation of artemether/lumefantrine, drugs that prolong the QT interval, including quinidine and quinine, should be used with caution.</p>
<p style="text-indent:-2em;margin-left:4em;">• Duplicate therapy: Antimalarials should not be given concomitantly unless there is no other treatment option.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Not indicated for the treatment of severe or complicated malaria or for the prevention of malaria.</p>
<p style="text-indent:-2em;margin-left:4em;">• Recrudescence: In the event of disease reappearance after a quiescent period, patients should be treated with a different antimalarial drug.</p></div>
<div class="block foc drugH1Div" id="F7726707"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Coartem: Artemether 20 mg and lumefantrine 120 mg [scored; contains polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F7725447"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16321948"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Coartem Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20-120 mg (per each): $6.74</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F52614224"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer with a full meal for best absorption. For infants, children, and patients unable to swallow tablets: Crush tablet and mix with 5 to 10 mL of water in a clean container; administer; rinse container with water and administer remaining contents. The crushed mixture should be followed with food/milk, infant formula, pudding, porridge, or broth if possible. Repeat dose if vomiting occurs within 2 hours of administration; for persistent vomiting, explore alternative therapy.</p></div>
<div class="block adm drugH1Div" id="F7726705"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Administer with a full meal for best absorption. For patients unable to swallow tablets: Crush tablet and mix with 5-10 mL of water. Administer to patient. Rinse container with water and administer contents to the patient. The crushed mixture should be followed with food/drink if possible. Repeat dose if vomiting occurs within 2 hours of administration; for persistent vomiting, explore alternative therapy.</p></div>
<div class="block sts drugH1Div" id="F7725715"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).</p></div>
<div class="block usep drugH1Div" id="F53570103"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of acute, uncomplicated malaria infections due to <i>Plasmodium falciparum</i>, including malaria in geographical regions where chloroquine resistance has been reported (FDA approved in children ≥2 months [and at least 5 kg] and adults).</p></div>
<div class="block cyt drugH1Div" id="F13298772"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Induces</b> CYP3A4 (weak)</p></div>
<div class="block dri drugH1Div" id="F7734090"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Antimalarial Agents: May enhance the adverse/toxic effect of Artemether and Lumefantrine. Management: Artemether/lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option. If combined, monitor patients for increased toxicities of both agents, including QTc interval prolongation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atogepant: CYP3A4 Inducers (Weak) may decrease the serum concentration of Atogepant.  Management: For treatment of episodic migraine, the recommended dose of atogepant is 30 mg once daily or 60 mg once daily when combined with CYP3A4 inducers. When used for treatment of chronic migraine, use of atogepant with CYP3A4 inducers should be avoided.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ChlorproMAZINE: Antimalarial Agents may increase the serum concentration of ChlorproMAZINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: CYP3A4 Inducers (Weak) may decrease the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 Substrates (High risk with Inhibitors): Artemether and Lumefantrine may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease serum concentrations of the active metabolite(s) of Artemether and Lumefantrine. Specifically, concentrations of dihydroartemisinin (DHA), the active metabolite of artemether may be decreased. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Artemether and Lumefantrine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease serum concentrations of the active metabolite(s) of Artemether and Lumefantrine. Specifically, concentrations of dihydroartemisinin (DHA), the active metabolite of artemether may be decreased. CYP3A4 Inducers (Strong) may decrease the serum concentration of Artemether and Lumefantrine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase serum concentrations of the active metabolite(s) of Artemether and Lumefantrine. Specifically, concentrations of dihydroartemisinin (DHA), the active metabolite of artemether may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Artemether and Lumefantrine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Systemic): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Systemic). Specifically, concomitant use of antimalarial agents with dapsone may increase the risk of hemolytic reactions. Dapsone (Systemic) may enhance the adverse/toxic effect of Antimalarial Agents. Specifically, concomitant use of dapsone with antimalarial agents may increase the risk for hemolytic reactions.  Management: Closely monitor patients for signs/symptoms of hemolytic reactions with concomitant use of dapsone and antimalarial agents, particularly in patients deficient in glucose-6-phosphate dehydrogenase (G6PD), methemoglobin reductase, or with hemoglobin M.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Topical): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Topical). Specifically, the risk of hemolytic reactions may be increased.  Management: Consider avoidance of this combination when possible. If combined, closely monitor for signs/symptoms of hemolytic reactions. Patients with glucose-6-phosphate dehydrogenase deficiency may be at particularly high risk for adverse hematologic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efavirenz: May decrease serum concentrations of the active metabolite(s) of Artemether and Lumefantrine. Specifically, concentrations of dihydroartemisinin (DHA), the active metabolite of artemether may be decreased. Efavirenz may decrease the serum concentration of Artemether and Lumefantrine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Grapefruit Juice: May increase serum concentrations of the active metabolite(s) of Artemether and Lumefantrine. Specifically, concentrations of dihydroartemisinin (DHA), the active metabolite of artemether may be increased. Grapefruit Juice may increase the serum concentration of Artemether and Lumefantrine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Halofantrine: Artemether and Lumefantrine may enhance the QTc-prolonging effect of Halofantrine.  Management: Halofantrine and artemether/lumefantrine should not be used within 1 month of each other.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Agents (Indeterminate Risk - Avoid) may enhance the QTc-prolonging effect of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hormonal Contraceptives: CYP3A4 Inducers (Weak) may decrease the serum concentration of Hormonal Contraceptives.  Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration, and to continue back-up contraception for 28 days after discontinuing a weak CYP3A4 inducer to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: QT-prolonging Agents (Indeterminate Risk - Avoid) may enhance the QTc-prolonging effect of Levoketoconazole.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mequitazine: May enhance the QTc-prolonging effect of Artemether and Lumefantrine. Management: Consider alternatives to concomitant use of artemether/lumefantrine and mequitazine when possible. While this combination is not specifically contraindicated, mequitazine labeling describes this combination as discouraged.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nevirapine: May decrease serum concentrations of the active metabolite(s) of Artemether and Lumefantrine. Specifically, concentrations of dihydroartemisinin (DHA), the active metabolite of artemether may be decreased. Nevirapine may decrease the serum concentration of Artemether and Lumefantrine. Nevirapine may increase the serum concentration of Artemether and Lumefantrine. Specifically, lumefantrine concentrations may increase.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiMODipine: CYP3A4 Inducers (Weak) may decrease the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Protease Inhibitors: May increase the serum concentration of Artemether and Lumefantrine. Specifically, the concentrations of lumefantrine may be increased. Protease Inhibitors may decrease the serum concentration of Artemether and Lumefantrine. Specifically, concentrations of artemether and dihydroartemisinin (DHA), the active metabolite of artemether, may be decreased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Avoid) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selpercatinib: CYP3A4 Inducers (Weak) may decrease the serum concentration of Selpercatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): CYP3A4 Inducers (Weak) may decrease the serum concentration of Sirolimus (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): CYP3A4 Inducers (Weak) may decrease the serum concentration of Sirolimus (Protein Bound). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">St John's Wort: May decrease serum concentrations of the active metabolite(s) of Artemether and Lumefantrine. Specifically, concentrations of dihydroartemisinin (DHA), the active metabolite of artemether may be decreased. St John's Wort may decrease the serum concentration of Artemether and Lumefantrine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): CYP3A4 Inducers (Weak) may decrease the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: CYP3A4 Inducers (Weak) may decrease the serum concentration of Ubrogepant.  Management: Use an initial ubrogepant dose of 100 mg and second dose (if needed) of 100 mg when used with a weak CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F7725713"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Absorption of artemether and lumefantrine is increased in the presence of food. The bioavailability of artemether increases two- to threefold and lumefantrine increases 16-fold (particularly a high-fat meal). Administration with grapefruit juice may result in increased concentrations of artemether and/or lumefantrine and potentiate QT prolongation. Management: Administer with a full meal for maximal absorption. Avoid grapefruit juice.</p></div>
<div class="block dic drugH1Div" id="F7725716"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Administer with a full meal for best absorption. Patients should be encouraged to take with a meal as soon as food can be tolerated. Patients who remain averse to food during treatment should be closely monitored as the risk of recrudescence may be great.</p></div>
<div class="block rep_considerations drugH1Div" id="F53510676"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Artemether may reduce the effectiveness of hormonal contraceptives. An additional nonhormonal method of birth control should be used during therapy.</p></div>
<div class="block pri drugH1Div" id="F7725578"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">A meta-analysis of observational pregnancy studies, which included 500 pregnant women exposed to artemether/lumefantrine in their first trimester, and data from observational and open-label studies of &gt;1,200 pregnant women exposed to artemether/lumefantrine in their second or third trimesters have not shown an increased risk of major birth defects, miscarriage, or adverse maternal/fetal outcomes.</p>
<p style="text-indent:0em;margin-top:2em;">Malaria infection during pregnancy may be more severe than in nonpregnant people and has a high risk of maternal and perinatal morbidity and mortality. Malaria infection during pregnancy can lead to miscarriage, premature delivery, low birth weight, congenital infection, and/or perinatal death. Therefore, pregnant patients are advised to avoid travel to malaria-risk areas. When travel is unavoidable, pregnant patients should take precautions to avoid mosquito bites and use effective prophylactic medications (CDC 2023; CDC Yellow Book 2024).</p>
<p style="text-indent:0em;margin-top:2em;">Artemether/lumefantrine may be used to treat chloroquine-resistant uncomplicated malaria due to <i>P. falciparum</i> during any trimester of pregnancy. The use of artemether/lumefantrine for the treatment of severe malaria during pregnancy is the same as for nonpregnant patients (CDC 2023). Consult current CDC malaria guidelines.</p></div>
<div class="block mopp drugH1Div" id="F53570105"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor for adequate food consumption (to ensure absorption and efficacy); ECG monitoring is advised if concomitant use of other agents that prolong the QT interval is medically required or patients with significant hypokalemia or hypomagnesemia.</p></div>
<div class="block pha drugH1Div" id="F7726703"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">A coformulation of artemether and lumefantrine with activity against <i>Plasmodium falciparum</i>. Artemether and major metabolite dihydroartemisinin (DHA) are rapid schizontocides with activity attributed to the endoperoxide moiety common to each substance. Artemether inhibits an essential calcium adenosine triphosphatase. The exact mechanism of lumefantrine is unknown, but it may inhibit the formation of β-hematin by complexing with hemin. Both artemether and lumefantrine inhibit nucleic acid and protein synthesis. Artemether rapidly reduces parasite biomass and lumefantrine eliminates residual parasites.</p></div>
<div class="block phk drugH1Div" id="F7725803"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Artemether: Rapid; Lumefantrine: Initial absorption at 2 hours; enhanced with food</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Artemether: 95%; Dihydroartemisinin (DHA): 47% to 76%; Lumefantrine: 99.7%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism:</p>
<p style="text-indent:-2em;margin-left:4em;">Artemether is hepatically metabolized to an active metabolite, dihydroartemisinin (DHA), catalyzed predominately by CYP3A4/5 and to a lesser extent by CYP2B6, CYP2C9 and CYP2C19. The artemether/DHA AUC ratio is 1.2 after 1 dose and 0.3 after 6 doses which may indicate autoinduction.</p>
<p style="text-indent:-2em;margin-left:4em;">Lumefantrine is hepatically metabolized to desbutyl-lumefantrine by CYP3A4.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Absorption of artemether and lumefantrine is increased in the presence of food. The bioavailability of artemether increases two- to threefold and lumefantrine increases 16-fold (particularly a high-fat meal).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Artemether: 1-2 hours; DHA: 2 hours; Lumefantrine: 72-144  hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: Artemether: ~2 hours; Lumefantrine: ~6-8 hours</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F11390222"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Riamet</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Riamet</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Arexel | Artemet | Coartem</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Riamet</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Artefan | Artemether + lumefantrine | Artiz dp | Artiz forte | Artrine | Asmether l | Aurother | Bimalaril | Chinther | Coartem | Colart | Combiart | Falsiban | Fantem ds | Fantem forte | Lufamet ds | Lufamet forte | Lufanter | Lumart | Lumartem | Lumiter | R lume | Tarlum | Tonlum</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Riamet</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Coartem</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Riamet</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Actpro al | Alfacure | Alumet | Arinax | Artefan | Artemether lumefantrine | Arthepa plus | Artilum | Artiz dp | Artiz forte | Artluf forte | Artrim | Artrin | Artrine | Asmether l | Bimalaril | Chinter | Coartem | Cofantrine | Combiart | Comether | Danmether | Falsiban | Fantem | Fantem ds | Fantem forte | Gen M | Lariact ds | Lariact forte | Laritem | Lonart ds | Lufamet ds | Lufamet forte | Lufanter | Lufar | Lufemax | Lufenart forte | Lum artem | Lumalaria | Lumart | Lumate plus | Lumether | Lumfart | Lumiart | Lumiforte | Lumiter | Lumiter ds | Lyater | Malarid | Malarid junior | Malatrine | Molumet | Novamether | Novamether ds | Novamether forte | Palumart | Palutor | Paluva | Plasmocid | Pomex | R lume | Shal artem | Sharlum | Tonlum</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Compound artemether</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Coartem | Komefan</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Riamet</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Riamet</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Malari co</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Arte L | Artemether + lumefantrine | Azunate L | Coartem | Combiart | Lumartem</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Riamet</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Riamet</span>;</li>
<li>
<span class="countryCode">(GH)</span> <span class="country">Ghana</span><span class="countrySeparator">: </span><span class="drugName">Artefan | Artemether + lumefantrine | Coartem | Danmether | Ibather | Lonart | Lumartem | Novamether forte</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Riamet</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Coartem</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Riamet</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Alvemether | Arh l | Arsulum | Arte Plus | Arteo Lf | Artinate l | Benther al DS | Benther ds | Chinther | Coartrin | Combither | Corother lf | Dinate lf | Falciget l | Falcinil Lf | Falcinil Lfx | Falcirid | Falcynate Lf | Famal l | Fesunate l | Lonart | Lumaria | Lumart | Lumbest | Lumerax | Lumet | Lumether | Maladex | Malatrit El | Match Plus | Oltimate l | Plasmorid | Quitoria | Resugo al | Rezatrin | Sviz Lf</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Riamet</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Al bel | Altem | Arexel | Artecure | Artefan | Artemether &amp; lumefantrine | Artemether and lumefantrine | Artemether Lumefantrine IPCA Laboratories | Artrin | Co corither ds | Co falcinum | Co malather | Co malather compact | Co max | Coartem | Combiart | Fantem ds | Fantem forte | Game | Hilact plus | Komefan 140 | Komefan 280 | Lamitar am | Lartem | Lartem forte | Lonart | Lonart forte | Lufanate | Lum artem | Lum artem forte | Lumerax | Lumet | Lumether | Lumiter | Luteriam | Malarate | Malarem | Malither l | Medistan al | Pro fantrine forte | Shal artem | Shal artem forte | Temtrin</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Coartem</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Riamet</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Riamet</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Riamet</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Actaphan | Actimax | Aflotin | Agwoiba | Alefer qs | Amakin artemether | Amatem forte | Anntifaa | Anntifaa forte | Arenax plus | Arteforth-80/480 | Artelum | Artelumex | Artelumex forte | Artemate plus | Artemef | Artemefan | Artemelum forte | Artemether &amp; lumefantrine | Artemether + lumefantrine | Artemether and lumefantrin | Artemether and lumefantrine | Artemether marcolivia | Artemether plus | Artemether/lumefantrine | Artemther &amp; lumefantrine | Artenate | Artenif | Artenif forte | Artepref | Artetrine | Artheget ez | Athelutrin forte | Avromal | Bgmal | Breartem | Breartem forte | Burstmal | Cachart | Cachart forte | Chimartem | Clartem | Clartem ds | Cledimal forte | Co fanart forte | Co lutem | Co malather | Colart | Combisunate | Contrine | Corexat | Cuzi artemether and lumefantrine | Danmether | Dimether qs | Dioartem | Eden artemether and lumefantrine | Exumal | Falcither forte | Ferife ds | Gloatem ds | Gloatem forte | Hanmal | Hyten | Jinart qs | Kaditrine | Kart lu | Kesartem | Kickmal | Killmal | Krishat artemether lumefantrine | Lariact | Lariact forte | Laritin | Laritin forte | Lavinart | Lokmal | Lokmal qs | Lomasyl | Lomasyl ds | Lonart | Lonart ds | Lumaforce | Lumaglobe | Lumal | Lumapil forte | Lumareal | Lumef forte | Lumerax | Lumetrinfast | Lynsunate forte | Malaid | Malanter ds | Maleright ds | Maleright forte | Maloff | Maltefan | Manifan | Manifan forte | Medither | Melumed | Metherine forte | Mikatem | Nancimal plus | Netmal | Nilmala | Norinate | Ogamal | Osymal | Osymal forte | Pacimal | Pharmaten qs | Pro fantrine | Ravimal adult | Rolother forte | Rotem plus | Sealther | Shal artem | Softmal | Sunshine coopharm artemether lumefantrine | Tamether fort | Telufan | Tiotem | Urzatem | Voather forte | Zartex | Zexit | Zexit forte</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Riamet</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Malaria | Riamet</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Coartem</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">A Fantrine | A mal | Alar | Almufin | Altis ds | Altis plus | Altum | Alumax | Alumax forte | Am invo | Amther | Antmal | Arceva | Arlofin | Arlofin ds | Arlofin forte | Arlufa | Arlumed | Arlumed ds | Armeth | Armeth ds | Arsomether l | Arte | Arteblax l | Arteblax l hd | Artecxin | Artelum | Artemate | Artemax ds | Artemet | Artemex L | Artenor | Arthebax ds | Arthefant ds | Artheget ds | Artheget ez | Arthenate ds | Arti | Artidol | Artil | Artilis | Artilis ds | Artimal | Artimal forte | Artimet | Artinag | Artine ds | Artrin | Artrin ds | Artrine | Artrine forte | Artrine plus | Astin ds | Atrilas plus | Benmether | Bio lumefar | Cibuther | Cibuther ds | Cibuther ds plus | Co Art | Co maledox | Co mether | Co Misomal | Coarbid | Defal | Di mether | Eptrim ds | Eptrim m | Eptrim x | Exafal | Examal | Falci | Falcim | Falcither | Falume | Falume ds | Falume ez | Fanart | Fantar | Feverest max | Finpher plus | Flydote | Gen M | Glact | Herart | Herme | Hi Servin | Hike | Inart | Inart ds | Inart forte ds | Indomal | Ixalt ez | Kohsar ds | Kp arther | Kurida | Leumef | Lumairia | Lumeart forte | Lumerax | Lumerax forte | Lumetrin | Lumix | Lumy a | Luther forte | M cure | Mac Mether | Mal Anx | Mala | Mala ds | Mala extra | Malafantrine pf | Malagon AL Forte | Malamether ds | Malamether forte | Malamether plus | Malazon | MalEra | Malera Max | Malfix | Malfix ds | Malgo | Maloff | Maltem plus | Malther | Marither | Marlin | Marlin ds | Marlin fort | Martifin | Martifin ds | Mcure | Mediarthem | Mega mether | Methodar | Morte | Morvella | Morvi | Mosnil | Mospro | Nolaria | Nolaria ds | Nolaria ez | One 3 | Ortim | Plimether | Plimether forte | Qmetem | Radimether | Rayart | Relyon | Rnofer | Rotrif | Rtx | Rtx plus | Safart | Saimether | Swiss mether | Synfant | Temprin | Temprin plus | Thermafane | Ufan | Welart ds | Welart forte | Wimlox | Winterm | Xomal Plus</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Riamet</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Coartem</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Airalam | Fluminoc | Riamet</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Coartem</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Riamet</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Riamet</span>;</li>
<li>
<span class="countryCode">(SL)</span> <span class="country">Sierra Leone</span><span class="countrySeparator">: </span><span class="drugName">Bi cortem | Colart | Fanther | Lonart ds | Lonart forte | Lufant | Lumatrona | Lumet | Malluart</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Coartem</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Livmether</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Artefan | Artefan 40/240 | Artemether/lumefantrine | Cach art | Cach art ds | Co arlumether forte | Co mether | Coart | Coartem | Combiart | Komefan | Lonart | Lonart ds | Lonart forte | Lumaren | Lumartem | Lumether | Lumiter</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Coartem</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Artefan | Artemether + lumefantrine | Cach art | Co malather | Co max | Coartem | Duomal | Fantem | Komefan | Lamitar am | Lonart | Lonart ds | Lonart forte | Luma | Lumartem | Lumet forte | Lumether | Shal artem | Shal artem forte</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Artefan | Artemether/lumefantrine | Coartem | Combiart | Komefan 140 | Komefan 280 | Lumartem | Lumet | Lumiter</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-16407341">
<a name="16407341"></a>Alecrim MG, Lacerda MV, Mourão MP, et al, “Successful Treatment of <i>Plasmodium falciparum</i> Malaria With a Six-Dose Regimen of Artemether-Lumefantrine Versus Quinine-Doxycycline in the Western Amazon Region of Brazil,” <i>Am J Trop Med Hyg</i>, 2006, 74(1):20-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/artemether-and-lumefantrine-pediatric-drug-information/abstract-text/16407341/pubmed" id="16407341" target="_blank">16407341</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29649190">
<a name="29649190"></a>Ballard SB, Salinger A; MPHc, Arguin PM, Desai M, Tan KR. Updated CDC recommendations for using artemether-lumefantrine for the treatment of uncomplicated malaria in pregnant women in the United States. <i>MMWR Morb Mortal Wkly Rep</i>. 2018;67(14):424-431. doi: 10.15585/mmwr.mm6714a4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/artemether-and-lumefantrine-pediatric-drug-information/abstract-text/29649190/pubmed" id="29649190" target="_blank">29649190</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Centers for Disease Control and Prevention (CDC). <i>CDC Yellow Book 2024: Health Information for International Travel</i>. Oxford University Press; 2023. <a href="https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/malaria" target="_blank">https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/malaria</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2">
<a name="CDC.2"></a>Centers for Disease Control and Prevention (CDC). Treatment of malaria: guidelines for clinicians (United States). <a href="https://www.cdc.gov/malaria/diagnosis_treatment/clinicians1.html" target="_blank">https://www.cdc.gov/malaria/diagnosis_treatment/clinicians1.html</a>. Updated June 28, 2023. Accessed July 26, 2023.</div>
</li>
<li>
<div class="reference">
                  Coartem (artemether and lumefantrine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; August 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16760509">
<a name="16760509"></a>Makanga M, Premji Z, Falade C, et al, “Efficacy and Safety of the Six-Dose Regimen of Artemether-Lumefantrine in Pediatrics With Uncomplicated <i>Plasmodium falciparum</i> Malaria: a Pooled Analysis of Individual Patient Data,” <i>Am J Trop Med Hyg</i>, 2006, 74(6):991-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/artemether-and-lumefantrine-pediatric-drug-information/abstract-text/16760509/pubmed" id="16760509" target="_blank">16760509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19265453">
<a name="19265453"></a>McGready R, Tan SO, Ashley EA, et al, “A Randomised Controlled Trial of Artemether-Lumefantrine Versus Artesunate for Uncomplicated <i>Plasmodium falciparum</i> Treatment in Pregnancy,” <i>PLoS Med</i>, 2008, 5(12):e253.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/artemether-and-lumefantrine-pediatric-drug-information/abstract-text/19265453/pubmed" id="19265453" target="_blank">19265453</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16235412">
<a name="16235412"></a>Omari AA, Gamble C, and Garner P, “Artemether-Lumefantrine (Six-Dose Regimen) for Treating Uncomplicated <i>Falciparum</i> Malaria,” <i>Cochrane Database Syst Rev</i>, 2005, Issue 4, Art. No.: CD005564.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/artemether-and-lumefantrine-pediatric-drug-information/abstract-text/16235412/pubmed" id="16235412" target="_blank">16235412</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15109547">
<a name="15109547"></a>Toovey S and Jamieson A, “Audiometric Changes Associated With the Treatment of Uncomplicated <i>Falciparum</i> malaria With Co-Artemether,” <i>Trans R Soc Trop Med Hyg</i>, 2004, 98(5):261-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/artemether-and-lumefantrine-pediatric-drug-information/abstract-text/15109547/pubmed" id="15109547" target="_blank">15109547</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). WHO guidelines for malaria (2023). https://www.who.int/publications/i/item/guidelines-for-malaria. Published March 14, 2023. Accessed July 20, 2023.</div>
</li></ol></div><div id="topicVersionRevision">Topic 12805 Version 235.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
